Immunome (IMNM) Research & Development (2019 - 2026)
Immunome's (IMNM) quarterly Research & Development came in at $46.4 million in Q1 2026, up 25.79% YoY from $36.9 million in Q1 2025, and down 8.64% on a QoQ basis from $50.8 million in Q4 2025.
Immunome (IMNM) Research & Development (2019 - 2026) Analysis & Trends
Immunome (IMNM) has 8 years of Research & Development data on file, last reported at $46.4 million in Q1 2026.
- Quarterly Research & Development rose 25.79% year-over-year to $46.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $186.8 million (up 23.67% YoY) and the FY2025 annual result came in at $177.3 million, up 36.86% from the prior year.
- Research & Development slipped to $46.4 million in Q1 2026, from $50.8 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $50.8 million in Q4 2025 to a low of $3.8 million in Q3 2023.
- A 5-year average of $23.5 million and a median of $15.4 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development sank 51.56% — and 2024, when it surged 873.06%.
- Tracing IMNM's Research & Development over 5 years: stood at $4.3 million in 2022, then jumped by 126.65% to $9.6 million in 2023, then surged by 396.94% to $47.9 million in 2024, then climbed by 6.01% to $50.8 million in 2025, then declined by 8.64% to $46.4 million in 2026.
- The last three Research & Development figures came in at $46.4 million (Q1 2026), $50.8 million (Q4 2025), and $49.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Immunome | 3.09 Bn | 2.57 Bn | - | 59.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.89 Mn |
| Mar 31, 2026 | 46.38 Mn |
| Dec 31, 2025 | 50.77 Mn |
| Sep 30, 2025 | 49.19 Mn |
| Jun 30, 2025 | 40.45 Mn |
| Mar 31, 2025 | 36.87 Mn |
| Dec 31, 2024 | 47.89 Mn |
| Sep 30, 2024 | 37.20 Mn |
| Jun 30, 2024 | 29.08 Mn |
| Mar 31, 2024 | 15.37 Mn |
| Dec 31, 2023 | 9.64 Mn |
| Sep 30, 2023 | 3.82 Mn |
| Jun 30, 2023 | 5.72 Mn |
| Mar 31, 2023 | 3.91 Mn |
| Dec 31, 2022 | 4.25 Mn |
| Sep 30, 2022 | 5.23 Mn |
| Jun 30, 2022 | 5.72 Mn |
| Mar 31, 2022 | 8.08 Mn |
| Dec 31, 2021 | 4.39 Mn |
| Sep 30, 2021 | 4.51 Mn |